International Journal of Antimicrobial Agents
Volume 36, Issue 4 , Pages 332-339 , October 2010

Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept

  • Jason A. Roberts

      Affiliations

    • Burns, Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, Australia
    • Pharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, Australia
    • Department of Intensive Care, Royal Brisbane and Women's Hospital, Brisbane, Australia
    • Corresponding Author InformationCorresponding author. Present address: Burns Trauma and Critical Care Research Centre, Level 3 Ned Hanlon Building, Royal Brisbane and Women's Hospital, Butterfield Street, Brisbane, Queensland 4029, Australia. Tel.: +61 7 3636 4108; fax: +61 7 3636 3542.
    • ,
  • Marta Ulldemolins

      Affiliations

    • Burns, Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, Australia
    • Critical Care Department, Vall d’Hebron University Hospital; Institut de Recerca Vall d’Hebron-Universitat Autònoma de Barcelona (UAB)-CIBER Enfermedades Respiratorias, Barcelona, Spain
    • ,
  • Michael S. Roberts

      Affiliations

    • Therapeutics Research Unit, The University of Queensland, Brisbane, Australia
    • School of Pharmacy, University of South Australia, Adelaide, Australia
    • ,
  • Brett McWhinney

      Affiliations

    • Department of Chemical Pathology, Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, Australia
    • ,
  • Jacobus Ungerer

      Affiliations

    • Department of Chemical Pathology, Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, Australia
    • ,
  • David L. Paterson

      Affiliations

    • Department of Infectious Diseases, Royal Brisbane and Women's Hospital, Brisbane, Australia
    • University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane, Australia
    • ,
  • Jeffrey Lipman

      Affiliations

    • Burns, Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, Australia
    • Department of Intensive Care, Royal Brisbane and Women's Hospital, Brisbane, Australia

Received 16 May 2010 ,Accepted 9 June 2010.

References 

  1. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37:840–851
  2. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003;31:2742–2751
  3. Garnacho-Montero J, Aldabo-Pallas T, Garnacho-Montero C, Cayuela A, Jiménez R, Barroso S, et al. Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. Crit Care. 2006;10:R111
  4. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003;115:529–535
  5. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115:462–474
  6. Bakker-Woudenberg IA, Roosendaal R. Impact of dosage schedule of antibiotics on the treatment of serious infections. Intensive Care Med. 1990;16(Suppl. 3):S229–S234
  7. Gomez CM, Cordingly JJ, Palazzo MG. Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother. 1999;43:1798–1802
  8. Lipman J, Wallis SC, Rickard CM, Fraenkel D. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med. 2001;27:363–370
  9. Roberts JA, Kirkpatrick CMJ, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64:142–150
  10. Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis—bolus versus continuous administration?. Crit Care Med. 2009;37:926–933
  11. Joukhadar C, Frossard M, Mayer BX, Brunner M, Klein N, Siostrzonek P, et al. Impaired target site penetration of β-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med. 2001;29:385–391
  12. Scaglione F. Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents. 2002;19:349–353
  13. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–10
  14. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol. 2004;2:289–300
  15. Ariano RE, Nyhlén A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother. 2005;39:32–38
  16. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007;51:1725–1730
  17. Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44:357–363
  18. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31:345–351
  19. Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49:4920–4927
  20. Craig W. Pharmacokinetic and experimental data on β-lactam antibiotics in the treatment of patients. Eur J Clin Microbiol Infect Dis. 1984;3:575–578
  21. Mouton JW, Vinks AA, Punt NC. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother. 1997;41:733–738
  22. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988;158:831–847
  23. Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother. 1985;15(Suppl. A):37–46
  24. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994;38:931–936
  25. Mouton JW, Vinks AA. Continuous infusion of β-lactams. Curr Opin Crit Care. 2007;13:598–606
  26. Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Vink-van den Berg JC, Michel BM. Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur J Clin Microbiol Infect Dis. 1989;8:878–887
  27. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr. 1986;108:835–840
  28. Ryan DM. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother. 1993;31(Suppl. D):1–16
  29. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49:1–16
  30. McWhinney BC, Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer JPJ. Analysis of twelve beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatograph B. 2010;878:2039–2043
  31. Buijk SL, Gyssens IC, Mouton JW, Van Vliet A, Verbrugh HA, Bruining HA. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother. 2002;49:121–128
  32. Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother. 1999;43:309–311
  33. Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother. 1999;43:2559–2561
  34. Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother. 2001;47:421–429

PII: S0924-8579(10)00249-9

doi: 10.1016/j.ijantimicag.2010.06.008

International Journal of Antimicrobial Agents
Volume 36, Issue 4 , Pages 332-339 , October 2010

Article Tools

* Image Usage & Resolution